US FDA ODAC backs Novartis’ Afinitor, Pfizer’s Sutent in rare pancreatic cancers
This article was originally published in Scrip
Executive Summary
The US FDA's Oncologic Drugs Advisory Committee (ODAC) on 12 April backed approval of Novartis' Afinitor (everolimus) as a treatment for patients with a rare type of cancer, known as pancreatic neuroendocrine tumors (PNETs), voting unanimously that the drug's benefits outweighed its risks based on the medicine's demonstrated efficacy and safety profile.